Premium
Optimising management of deferasirox therapy for patients with transfusion‐dependent thalassaemia and lower‐risk myelodysplastic syndromes
Author(s) -
Kattamis Antonis,
Aydinok Yesim,
Taher Ali
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13111
Subject(s) - deferasirox , myelodysplastic syndromes , medicine , chelation therapy , deferiprone , discontinuation , deferoxamine , thalassemia , adverse effect , intensive care medicine , pediatrics , bone marrow
Effective iron chelation therapy is an important part of treatment in patients with transfusion‐dependent thalassaemia and lower‐risk myelodysplastic syndromes ( MDS ). Key strategies for optimising iron chelation therapy include ensuring good adherence and preventing and managing adverse events ( AE s). Good adherence to iron chelation therapy with deferoxamine and deferasirox has been linked to improved survival and/or reductions in complications related to iron overload; however, maintaining good adherence to iron chelators can be challenging. Patients with transfusion‐dependent thalassaemia or lower‐risk MDS showed better adherence to the deferasirox film‐coated tablet ( FCT ) formulation than to the deferasirox dispersible tablet formulation in the ECLIPSE trial, reflecting in part the improved palatability and convenience of deferasirox FCT . As well as affecting adherence, AE s may lead to dose reduction, interruption or discontinuation, resulting in suboptimal iron chelation therapy. Preventing and successfully managing AE s may help limit their impact on adherence, and following dosage and administration recommendations for iron chelators such as deferasirox may help minimise AE s and optimise treatment in patients with transfusion‐dependent thalassaemia and lower‐risk MDS .